DLBS3233 is a standardized extract made from a combination of Lagerstroemia speciosa and Cinnamomum burmannii. These plants are well-known for their antidiabetic properties. DLBS3233 has been studied in vitro, in vivo, and through clinical studies, demonstrating its effectiveness as a treatment for people with type 2 Diabetes and possibly also for diabetes prevention.
Product Overview
Botanical origin
Cinnamomum burmannii
Lagerstroemia speciosa
Type of extract
Dry extract
Analytical markers: Proanthocyanidin A-trimer, Ellagic acid, and Total Phenolic Compounds
Product Specification
1. Premium Quality and Standardization
DLBS3233 is a standardized herbal extract crafted to meet stringent quality specifications.
2. Manufactured in a Certified Facility
Produced in a facility with GMP and ISO 22000 certifications, ensuring top-tier quality.
Guaranteed Halal through the implementation of the Halal Assurance System.
3. Proven Safety Through Rigorous Studies
DLBS3233 has proven to be safe through acute toxicity, 9-month chronic toxicity, 90-day subchronic toxicity, and teratogenic studies.
4. Scientifically Proven benefits
The benefits of DLBS3233 has been scientifically proven through pharmacodynamic study, conducted on insulin-resistant rats.
The benefits of DLBS3233 in improving Type-2 diabetes have been clinically studied in prediabetic and type-2 diabetes patients.
Key Feature of the Product
Regulates Blood Glucose, Insulin, and Cholesterol Levels
Preclinical studies on insulin-resistant rats showed the extract effectively regulates blood glucose, insulin, and cholesterol levels, with a significant reduction in the HOMA index.
Improves Glycemic Control in Type-2 Diabetes Patients
A clinical study demonstrated that combining the extract with oral antidiabetic agents significantly reduced HbA1c levels after six weeks of treatment.
A marked reduction in insulin resistance (HOMA-R) and an increase in adiponectin levels were observed after twelve weeks of treatment, indicating enhanced glycemic control and metabolic health.
Prevents Diabetes Progression in Prediabetic Patients
A clinical trial on prediabetic patients revealed a reduction in HOMA-IR and improved beta-cell performance, highlighting the extract’s potential to prevent the onset of diabetes.
Low Risk of Hypoglycemia
Clinical trials on non-obese healthy individuals with normal glucose levels confirmed that the extract is associated with a low risk of causing hypoglycemia, ensuring safe usage.
Health Benefit
Store at room temperature (≤ 30°C), in a tight container, protect from direct sunlight.
Storage Conditions
Product Information of Inlacin and HerbaWELL Diabetadex